CyFlow CD264 PE (RUO)
| 品番 | CY292936 | ||
|---|---|---|---|
| 抗体名 | Anti-Hu CD264 PE,TRAIL-R4-01 | ||
| 包装単位 | 0.1 mg | ||
| 濃度 | 0.1 mg/ml | ||
| 推奨使用量 | - | ||
| 容量 | 1 ml | ||
| 関連製品 (アイソタイプコントロール) |
Mouse IgG1 PE (BV655324) |
||
| 反応性|交差吸着 | Human | レーザー | Blue, Green, Yellow |
| 抗原 | CD264, TRAIL-R4, DCR2 | 最大蛍光波長 | 576 nm |
| クローン | TRAIL-R4-01 | 最大励起波長 | 496 nm, 565 nm |
| ホスト | Mouse | 標識/Format | PE |
| アイソタイプ | IgG1 | 研究分野 | Immunophenotyping | Apoptosis |
| クローナリティ | monoclonal | アプリケーション | - |
Anti-Hu CD264 PE,TRAIL-R4-01
特異性
The mouse monoclonal antibody TRAIL-R4-01 recognizes CD264 (TRAIL-R4) antigen, a 42 kDa transmembrane protein expressed on various blood cells.
抗原情報
CD264 (TRAIL-R4, TR4, DcR2, TRUNDD), expressed mainly on CD8+ and NK cells, belongs to receptors of TRAIL, a TNF-like membrane toxic protein that induces apoptosis in many tumor cells, but not in normal cells. TRAIL-R4, however, contains partially truncated death domain, thus it is unable to induce apoptosis and serves as a negative regulator of apoptotic signaling by impairment death-inducing signaling complex (DISC) processing. TRAIL-R4 interacts with death receptor 5 (DR5) in the native DISC in a TRAIL-dependent manner and prevents its corecruitment with death receptor 4 (DR4).
利用方法
The reagent is designed for Flow Cytometry analysis. Suggested working usage is 3 µg/ml. Indicated dilution is recommended starting point for use of this product, but working concentrations should be validated by the investigator.
保存方法
Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
安定性情報
Do not use after expiration date stamped on vial label.
レファレンス
• Clancy L, Mruk K, Archer K, Woelfel M, Mongkolsapaya J, Screaton G, Lenardo MJ, Chan FK: Preligand assembly domain‑mediated ligand‑independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL‑induced apoptosis. Proc·Natl·Acad·Sci·USA. 2005·Dec·13; 102(50):18099‑104. <·PMID:·16319225·>
• Deligezer U, Dalay N: Expression of the TRAIL Receptors in Blood Mononuclear Cells in Leukemia. Pathol·Oncol·Res. 2007; 13(4):290‑4. <·PMID:·18158563·>
• Falschlehner C, Emmerich CH, Gerlach B, Walczak H: TRAIL signalling. Int·J·Biochem·Cell·Biol. 2007; 39(7‑8):1462‑75. <·PMID:·17403612·>
• Mérino D, Lalaoui N, Morizot A, Schneider P, Solary E, Micheau O: Differential inhibition of TRAIL‑mediated DR5‑DISC formation by decoy receptors 1 and 2. Mol·Cell·Biol. 2006·Oct; 26(19):7046‑55. <·PMID:·16980609·>
• Sanlioglu AD, Dirice E, Aydin C, Erin N, Koksoy S, Sanlioglu S: Surface TRAIL decoy receptor‑4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells. BMC·Cancer. 2005·May·25; 5(1):54. <·PMID:·18518976·>